Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease

TOKYO, Apr 20, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer’s Disease with Lecanemab, an Anti-Abeta Protofibril Antibody, in the peer-reviewed journal Alzheimer’s Research and Therapy. The manuscript describes results... » read more

polly
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer’s Disease by Dian-Tu
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer’s Disease by Dian-Tu

TOKYO, Mar 16, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research between Eisai and University College London, has been selected by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) led by Washington University School of Medicine in... » read more

polly
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer’s Disease and Dementia at the 15th International Conference on Alzheimer’s and Parkinson’s Disease
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer’s Disease and Dementia at the 15th International Conference on Alzheimer’s and Parkinson’s Disease

TOKYO, Mar 5, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the latest data from its Alzheimer’s disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD2021) to be... » read more

polly
Eisai: Biogen Files New Drug Application for Aducanumab in Japan
Eisai: Biogen Files New Drug Application for Aducanumab in Japan

TOKYO, Dec 11, 2020 – (JCN Newswire) – Biogen and Eisai, Co., Ltd. (Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer’s disease. Aducanumab, an amyloid beta-targeting antibody, has been shown in clinical trials to... » read more

polly